Mobius Therapeutics Was Founded In 2006 On The Principle Of Resolution Of Challenges In The Ophthalmic Pharmaceutical Marketit S Flagship Productmitosolwas Approved By Fda In 2012 And Has Become Thegold Standardfor Preparation And Delivery Of Mitomycin C In The Ophthalmic Operating Room But It Does Not End Thereophthalmic Perioperative Injectables Are A Matter Of Daily Frustrationthey Are Often Off Labelmust Be Sourced In Inconvenient Compounded Formulationsare Presented In Enormousmulti Dose Vialsand Have Never Been Designed For Use In The Sterile Environment Of The Ophthalmic Or Mobius S Expanded Mission Is Founded On The Recognition Of These Needsand Subsequently Directing Our Efforts To The Optimization Of The Products To The Ophthalmic Oronly Then Do We Seek Regulatory Approvaloffering Providers And Patients The Security Of Fda Approved And Cgmp Compliant Productsdesigned From The Outset To Meet The Demanding Needs Of The Ophthalmic Or Our Current Portfolio Is Only The Beginningwith Major Products In Various Stages Of Design And Regulatory Submissionwe Look Forward To A Future Of Synergistic Collaboration With The Ophthalmic Community
No conferences found for this company.
| Company Name | Mobius Therapeutics Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
